BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 28067895)

  • 1. The NF1 gene in tumor syndromes and melanoma.
    Kiuru M; Busam KJ
    Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.
    Mahalingam M
    Adv Anat Pathol; 2017 Jan; 24(1):1-14. PubMed ID: 27941538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
    Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
    Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
    Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
    Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple roles of NF1 in the melanocyte lineage.
    Larribère L; Utikal J
    Pigment Cell Melanoma Res; 2016 Jul; 29(4):417-25. PubMed ID: 27155159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
    Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
    Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
    Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
    Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
    Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
    Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated molecular drivers coordinate biological and clinical states in melanoma.
    Conway JR; Dietlein F; Taylor-Weiner A; AlDubayan S; Vokes N; Keenan T; Reardon B; He MX; Margolis CA; Weirather JL; Haq R; Schilling B; Stephen Hodi F; Schadendorf D; Liu D; Van Allen EM
    Nat Genet; 2020 Dec; 52(12):1373-1383. PubMed ID: 33230298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF1 Mutations Are Common in Desmoplastic Melanoma.
    Wiesner T; Kiuru M; Scott SN; Arcila M; Halpern AC; Hollmann T; Berger MF; Busam KJ
    Am J Surg Pathol; 2015 Oct; 39(10):1357-62. PubMed ID: 26076063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF1 mutations in conjunctival melanoma.
    Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NF1 somatic mutational landscape in sporadic human cancers.
    Philpott C; Tovell H; Frayling IM; Cooper DN; Upadhyaya M
    Hum Genomics; 2017 Jun; 11(1):13. PubMed ID: 28637487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofibromatosis type 1 (NF1) gene: Beyond café au lait spots and dermal neurofibromas.
    Peltonen S; Kallionpää RA; Peltonen J
    Exp Dermatol; 2017 Jul; 26(7):645-648. PubMed ID: 27622733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental abnormalities and cancer predisposition in neurofibromatosis type 1.
    Larizza L; Gervasini C; Natacci F; Riva P
    Curr Mol Med; 2009 Jun; 9(5):634-53. PubMed ID: 19601812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.